Heron Therapeutics (HRTX) Tops Q4 EPS by 4c

Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Goldman "broadly" raises estimates for LTL and truckload stocks
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth